...
首页> 外文期刊>Biomaterials Science >Bifunctional liposomes reduce the chemotherapy resistance of doxorubicin induced by reactive oxygen species
【24h】

Bifunctional liposomes reduce the chemotherapy resistance of doxorubicin induced by reactive oxygen species

机译:双官能脂质体降低了反应性氧诱导的多柔比星的化疗抗性

获取原文
获取原文并翻译 | 示例
           

摘要

Doxorubicin (DOX) liposome is a widely used nano-medicine for colorectal cancer treatment. However, doxorubicin therapy increases the level of reactive oxygen species (ROS) in tumor cells, such as hydrogen peroxide (H2O2), which can stabilize hypoxia-inducible-factor-1 alpha (HIF-1 alpha). In a tumor hypoxic microenvironment, HIF-1 can up-regulate tumor-resistance related proteins, including P-glycoprotein (P-gp), glucose transporter 1 (GLUT-1), and matrix metalloproteinase 9 (MMP-9), leading to tumor tolerance to chemotherapy. The functional inhibition of HIF-1 can overcome this resistance and enhance the efficacy of tumor therapy. Here, we encapsulated one of the most effective HIF-1 inhibitors, acriflavine (ACF), and DOX in liposomes (DOX-ACF@Lipo) to construct bifunctional liposomes. ACF and DOX, released from DOX-ACF@Lipo, could effectively suppress the function of HIF-1 and the process of DNA replication, respectively. Consequently, the bifunctional liposome has great potential to be applied in clinics to overcome chemotherapy resistance induced by hypoxia.
机译:多柔比星(DOX)脂质体是一种广泛使用的纳米药,用于结直肠癌治疗。然而,多柔比蛋白治疗增加了肿瘤细胞中的活性氧物质(ROS)的水平,例如过氧化氢(H2O2),其可以稳定缺氧诱导因子-1α(HIF-1α)。在肿瘤缺氧微环境中,HIF-1可以上调肿瘤抗性相关蛋白质,包括p-糖蛋白(P-GP),葡萄糖转运蛋白1(GLUT-1)和基质金属蛋白酶9(MMP-9),导致肿瘤耐受化疗。 HIF-1的功能抑制可以克服这种抗性并增强肿瘤治疗的功效。在此,我们将最有效的HIF-1抑制剂,ARIFlavine(ACF)和DOX中的一种封装在脂质体(DOX-ACF @ LIPO)中以构建双官能脂质体。 ACF和DOX从DOX-ACF @ LIPO发布,可以有效地抑制HIF-1的功能和DNA复制过程。因此,双功能性脂质体具有巨大的潜力,可用于诊所以克服缺氧诱导的化疗抗性。

著录项

  • 来源
    《Biomaterials Science》 |2019年第11期|共8页
  • 作者单位

    Nanjing Tech Univ Coll Biotechnol &

    Pharmaceut Engn Nanjing 211816 Jiangsu Peoples R China;

    Nanjing Univ Med Sch State Key Lab Pharmaceut Biotechnol Nanjing 210093 Jiangsu Peoples R China;

    Nanjing Univ Med Sch State Key Lab Pharmaceut Biotechnol Nanjing 210093 Jiangsu Peoples R China;

    Nanjing Univ Med Sch State Key Lab Pharmaceut Biotechnol Nanjing 210093 Jiangsu Peoples R China;

    Nanjing Univ Med Sch State Key Lab Pharmaceut Biotechnol Nanjing 210093 Jiangsu Peoples R China;

    Nanjing Univ Med Sch State Key Lab Pharmaceut Biotechnol Nanjing 210093 Jiangsu Peoples R China;

    Nanjing Univ Med Sch State Key Lab Pharmaceut Biotechnol Nanjing 210093 Jiangsu Peoples R China;

    Nanjing Univ Med Sch State Key Lab Pharmaceut Biotechnol Nanjing 210093 Jiangsu Peoples R China;

    Nanjing Univ Med Sch State Key Lab Pharmaceut Biotechnol Nanjing 210093 Jiangsu Peoples R China;

    Nanjing Tech Univ Coll Biotechnol &

    Pharmaceut Engn Nanjing 211816 Jiangsu Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 分子生物学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号